Functionally Selective Inhibition of the Oxytocin Receptor by Retosiban in Human Myometrial Smooth Muscle
Open Access
- 7 January 2020
- journal article
- research article
- Published by The Endocrine Society in Endocrinology
- Vol. 161 (2)
Abstract
Context Novel small molecule inhibitors of the oxytocin receptor (OTR) may have distinct pharmacology and mode of action when compared to first generation oxytocin antagonists when used for the prevention of preterm birth. Objective To determine the mechanism of action of small molecule OTR antagonists retosiban and epelsiban in comparison to the currently used peptide-based compound atosiban. Design Human myometrial samples were obtained at cesarean section and subjected to pharmacological manipulations to establish the effect of antagonist binding to OTR on downstream signaling. Results Retosiban antagonism of oxytocin action in human myometrium was potent, rapid and reversible. Inhibition of inositol 1,4,5-trisphosphate (IP3) production followed single site competitive binding kinetics for epelsiban, retosiban and atosiban. Retosiban inhibited basal production of IP3 in the absence of oxytocin. Oxytocin and atosiban, but not retosiban inhibited forskolin and calcitonin stimulated cAMP production. Inhibition of cAMP was reversed by pertussis toxin. Oxytocin and atosiban, but not retosiban and epelsiban, stimulated ERK1/2 activity in a time a concentration dependent manner. Oxytocin and atosiban stimulated cyclo oxygenase 2 (COX2) activity and subsequent production of prostaglandin E2 and F2α. Prostaglandin production was inhibited by rofecoxib, pertussin toxin, and ERK inhibitor U0126. Oxytocin but not retosiban or atosiban stimulated coupling of the OTR to Gαq G-proteins. Oxytocin and atosiban but not retosiban stimulated coupling of the OTR to Gαi G-proteins. Conclusions Retosiban and epelsiban demonstrate distinct pharmacology when compared to atosiban in human myometrial smooth muscle. Atosiban displays agonist activity at micromolar concentrations leading to stimulation of prostaglandin production.Keywords
Funding Information
- GlaxoSmithKline
This publication has 23 references indexed in Scilit:
- Inhibition of ejaculation by the non‐peptide oxytocin receptor antagonist GSK557296: a multi‐level site of actionBritish Journal of Pharmacology, 2013
- Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential TherapeuticsJournal of Neuroendocrinology, 2012
- Characterization of the endocannabinoid system, CB1 receptor signalling and desensitization in human myometriumBritish Journal of Pharmacology, 2011
- The discovery of GSK221149A: A potent and selective oxytocin antagonistBioorganic & Medicinal Chemistry Letters, 2008
- Epidemiology and causes of preterm birthThe Lancet, 2008
- Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the ratAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2007
- Regulation of Oxytocin Receptors and Oxytocin Receptor SignalingSeminars in Reproductive Medicine, 2007
- Gq/11 and Gi/o activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor‐subtypeBritish Journal of Pharmacology, 2001
- Specific G protein activation and μ-opioid receptor internalization caused by morphine, DAMGO and endomorphin IEuropean Journal of Pharmacology, 1998
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976